28 Chinese Nucleic Acid Therapy Companies Led 2023 Fundraising Surge and Have Filed IPO Prospectuses

Nov 02, 2023 17:26 CST Updated 17:26

Sirius Therapeutics

Oligonucleotide Drug Developer

▎Edited by the WuXi AppTec content team

Recently, the Nobel Prize in Physiology or Medicine was awardedmRNAIn the vaccine field, the industry's attention is focused on the nucleic acid drug sector.。Nucleic acid drugs mainly include antisense oligonucleotides (ASO), small interfering RNA (siRNA), RNA aptamers, and messenger RNA (mRNA), etc.This article will focus on the field of nucleic acid drugs, an innovative therapy.A Brief Analysis of the Financing Trends in 2023 and Highlights Worth Noting for Readers' Reference.

According to incomplete statistics,From 2019 to 2023, there were over 400 financing events in the global nucleic acid drug field, and 76 financing events have occurred so far in 2023.ItsIn China, 37 financing events exceeded 100 million RMB, accounting for nearly 50% of the total.

Early-stage Financing in the Nucleic Acid Drug FieldDisplaySigns of Recovery:2023More than half (55%, 42 cases) were early-stage financing events.(Series A and before Series A); The total financing amount increased by 24% compared to 2022, reaching 7.9 billion yuan, and is expected to surpass the financing level of 2021. Currently, the highest single financing in this field also comes from the early stage — ReNAgade Therapeutics' Series A financing of over 300 million US dollars.

China's Nucleic Acid Sector Financing Heat Surpasses the US for the First Time: Dividing the financing events in the nucleic acid drug field in 2023 by the country or region where the companies are located reveals,The number of financing events from China is the highest,A total of 32 financing events occurred, making it the country with the highest number of financing events in this field in 2023, with a total financing amount of nearly 3 billion yuan.

# Jia Chen Xi Hai

On February 27, Immorna announced the completion of nearly US$100 million in Series A+ and A++ financing rounds. This round of financingWill be mainly used to support the advancement of multiple clinical trials and the development of preclinical pipelines. The company will also continue to deepen its industrial readiness and technological innovation, actively promoting mid-to-late stage clinical trials and commercialization.

Jia Chen West Sea was founded in 2019, with offices and CMC laboratories located in Hangzhou, Zhejiang.Focus on developing biotherapies and vaccines based on RNA technology, involving various RNA technology platforms such as conventional, self-replicating, and circular RNA.Since its establishment, the company has built a complete set of RNA synthesis, purification, and quality control processes, and has developed universal RNA templates with higher expression efficiency (including self-replicating and non-self-replicating RNA). With the help of its efficient screening platform, Sirius Therapeutics has developed a full range of RNA delivery systems, including polymers and lipid nanoparticle particles.

In July this year, JCXH independently developedmRNA Quadrivalent Seasonal Influenza Vaccine JCXH-107 New Drug Clinical TrialClinical Trial (IND) Application Approved by FDA.In addition, JCXH-211, a cytokine solid tumor therapeutic product based on self-replicating srRNA, JCXH-212, an srRNA cancer vaccine, JCXH-221, a broad-spectrum COVID-19 vaccine, and JCXH-105, a shingles vaccine, developed by Sirius Therapeutics have all entered Phase 1/2 clinical trials.

# Sirius Therapeutics

October 16 news, Sirius TherapeuticsSirius Therapeutics recently announced the completion of a $60 million Series B financing round to advance the clinical development of its siRNA novel therapy pipeline and the iterative innovation of next-generation nucleic acid delivery technology. This round of financing was led by H&K Capital, with participation from Prosperity Global Investment Fund. Existing investors Orbimed and Hongyuan Capital continued to increase their investments. To date, Sirius Therapeutics has raised nearly $100 million in cumulative financing.

Sirius Therapeutics was founded in 2021.Focus on the Development of Next-Generation Nucleic Acid Innovative Therapies in the Field of Cardiovascular Diseases.The company owns the core technology platform for small nucleic acid drug research and development and has its independent intellectual property rights. Currently, Sirius Therapeutics has established several differentiated product pipelines with "first-in-class" and "best-in-class" potential.

# Wisgen Bio

June 20,Wisgen Bio released a press release stating,Its Series A financing, totaling 300 million yuan, has been completed with investments from institutions such as Kangchen Pharmaceutical and Guanghua Wutong. This round of financing will be used to advance the research and development of cancer treatment vaccines and clinical trials both in China and overseas, accelerating the growth of Sirius Therapeutics.

WestSirius Biotech was founded in July 2021 by Professor Wei Yuquan and Professor Song Xiangrong. It is a pharmaceutical technology company focusing on the development of mRNA innovative drugs and adjuvants. Currently, the company has established an mRNA drug technology platform and a novel adjuvant platform, with over 20 product pipelines including preventive vaccines for antiviral purposes, vaccines for anti-tumor, aging, and obesity, as well as gene-editing products and novel adjuvants.

According to public information from Weisijin Biotechnology, the company has developed treatments for EBV-related tumors (such as nasopharyngeal carcinoma) and liver cancer.Two Universal Cancer Treatment Varieties (EBV-mRNA and HBV-mRNA), andmRNA Vaccine for SARS-CoV-2 Variant Strains and Novel AdjuvantHave already entered the clinical trial stage.

# TransmitBio

On June 27, Baik Biotech announced that it had signed an investment agreement and made an external investment in TheMedium.According to the R&D progress of Chuanxin Biotech's projects, Baik Biotech will gradually increase its investment in and acquire shares of Chuanxin Biotech, eventually holding 100% of its equity. In the first phase (i.e., this round of capital increase), Baik Biotech will subscribe for Chuanxin Biotech with RMB 150 million.Sirius Therapeutics increases registered capital. The overall investment cycle is approximately 3 to 4 years.

Public information shows that Sirius Therapeutics was founded in April 2021.Committed to the commercial development of RNA drugs, the companyThe founder is Dr. Jianxin Chen. By introducing this globally innovative LNP delivery technology, Sirius Therapeutics has established a complete mRNA drug research and development and large-scale production system.Rapid Development of Novel mRNA Vaccines for Infectious Diseases and CancerThe company has currently built a relatively complete R&D team, with core members covering multiple aspects such as target biology, RNA structural biology, mRNA synthesis, and LNP production, ensuring the rapid advancement of the company's pipeline products.

# Huanma Bio

On August 15, Huanma Bio announced the completion of a multi-million-dollar Series A financing round. This round of financingLed by Johnson & Johnson Innovation-JJDC, with String Fund and others following suitHuanma Biotech is aDevelopment of Nucleic Acid Drugs Based on a Unique Circular RNA Technology PlatformAn innovative biopharmaceutical company. This round of financing will be used to accelerate the company's pipeline advancement, promote the transformation of circular RNA technology into drugs, benefiting a wide range of patients.

RingCode Bio was founded in 2021, with the scientific founder also serving as a director.Professor Wang Zefeng, with high-level research achievements and technical accumulation in the regulatory mechanisms and engineering applications of circular RNA, and Dr. Yang Yun, co-founder and Chief Technology Officer (CTO) of Huanma Biotech, in RNA in vitro cyclization and circular RNA has many years of basic research and technical development experience in translation efficiency regulation and other aspects.

Readers, please star ⭐Chuangjianhui to receive push notifications in the first time.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media feeds, but unauthorized republication or reproduction in any form by media or institutions to other platforms is strictly prohibited. For authorization to republish, please contact"Chuangjian Hui"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommendations

Click "InSee", Sharing New Health Trends from Jingyin Therapeutics"